Table 6.
Univariable and multivariable regression table for follow-up CRM
| Follow-up concentric remodeling (CRM) | Univariable model (n = 51) | Multivariable (n = 43) | ||||
|---|---|---|---|---|---|---|
| OR | 95% CI | p-value | OR | 95% CI | p-value | |
| Demographics (baseline) | ||||||
| Age, per year | 1.02 | 0.97–1.07 | 0.49 | 1.01 | 0.93–1.09 | 0.76 |
| Male versus female | 1.6 | 0.37–6.91 | 0.53 | 1.25 | 0.15–10.6 | 0.84 |
| Race | ||||||
| White | REF | REF | REF | REF | ||
| Black | 3.78 | 0.65–22.02 | 0.14 | 3.82 | 0.60–24.4 | 0.84 |
| Hispanic | 1.74 | 0.48–6.28 | 0.39 | |||
| Other | … | … | … | |||
| BMI, per kg/m2 | 1.07 | 0.96–1.19 | 0.23 | 1.05 | 0.92–1.19 | 0.48 |
| RA characteristics | ||||||
| RA duration (square root), per year | 1.21 | 0.83–1.78 | 0.32 | … | … | … |
| Joint deformities (square root) | 1.28 | 0.83–1.97 | 0.27 | … | … | … |
| DAS28CRP (baseline) | 1.09 | 0.71–1.65 | 0.70 | … | … | … |
| DAS28CRP (follow-up) | 1.28 | 0.82–2.01 | 0.28 | … | … | … |
| Averaged DAS28CRP (baseline + fu) | 1.24 | 0.76–2.05 | 0.39 | … | … | … |
| CDAI (square root) (baseline) | 1.08 | 0.75–1.57 | 0.67 | … | … | … |
| CDAI (square root) (follow-up) | 1.14 | 0.80–1.62 | 0.46 | … | … | … |
| Averaged CDAI (baseline + fu) | 1.01 | 0.96–1.07 | 0.65 | … | … | … |
| RF (baseline) > 40, units | 2.9 | 0.44–19.3 | 0.27 | 0.26 | 0.046–1.50 | 0.13 |
| CCP (baseline) > 250, units | 1.17 | 0.36–3.76 | 0.79 | … | … | … |
| Square root CRP (baseline), per mg/liter | 1.29 | 0.84–1.97 | 0.24 | … | … | … |
| Square root CRP (follow-up), per mg/liter | 0.90 | 0.62–1.30 | 0.57 | … | … | … |
| Log IL-6 (baseline), per mg/liter | 1.44 | 0.87–2.37 | 0.15 | … | … | … |
| Log IL-6 (follow-up), per mg/liter | 1.52 | 0.89–2.61 | 0.13 | 2.55 | 0.99 − 6.58 | 0.053 |
| Log BNP (baseline), per pg/mL | 1.96 | 0.72–5.30 | 0.19 | 1.91 | 0.51–7.09 | 0.33 |
| Log troponin-I (baseline), per pg/mL | 1.06 | 0.61–1.85 | 0.83 | … | … | … |
| Log galectin-3 (baseline), per ng/mL | 1.43 | 0.41–4.97 | 0.57 | … | … | … |
| RA medications (follow-up) | ||||||
| NSAID use, yes versus no | 1.15 | 0.34–3.93 | 0.82 | … | … | … |
| Prednisone use, yes versus no | 0.79 | 0.067–9.44 | 0.85 | … | … | … |
| Hydroxychloroquine use, yes versus no | 3.87 | 0.33–46.05 | 0.28 | … | … | … |
| TNF inhibitors use, yes versus no | 0.83 | 0.25–2.80 | 0.77 | … | … | … |
| Tocilizumab use, yes versus no | 5.8 | 0.55–60.7 | 0.14 | … | … | … |
| CV risk factors | ||||||
| Current smoker, yes versus no | 0.79 | 0.067–9.44 | 0.85 | … | … | … |
| SBP (baseline), per mm/Hg | 0.998 | 0.96–1.03 | 0.87 | … | … | … |
| SBP (follow-up), per mm/Hg | 0.99 | 0.96–1.03 | 0.71 | … | … | … |
| Statin use (follow-up), yes versus no | 1.54 | 0.39–6.03 | 0.54 | … | … | … |
| ASA use (follow-up), yes versus no | 4.14 | 1.00 − 17.05 | 0.049 | 4.01 | 0.46–34.89 | 0.21 |
| Total cholesterol (follow-up), per mg/dl | 1.00 | 0.98–1.03 | 0.58 | … | … | … |
| LDL (follow-up), per mg/dl | 1.00 | 0.98–1.02 | 0.99 | … | … | … |
| HDL (follow-up), per mg/dl | 0.998 | 0.97–1.03 | 0.93 | … | … | … |
| Prob > χ2 | 0.0597 | |||||
| Pseudo R2 | 0.26 | |||||